Unknown

Dataset Information

0

Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.


ABSTRACT: OBJECTIVE:Patients with schizophrenia treated with antipsychotics often develop metabolic side effects including dyslipidemia. Antipsychotics potentially upregulate gene expression of a lipid metabolism pathway protein called SREBP via SREB transcription factors (SREBFs). Genetic variation within SREBF may contribute to dyslipidemias and lipid medication efficacy within schizophrenia. RESULTS:A cross-sectional study of 157 patients were genotyped for SREBF1 (rs11868035) and SREBF2 (rs1057217) variants, and assessed for fasting lipids. The cohort's mean age was 46.6 years, was 64% male and 86% were using atypical antipsychotics. When stratified by statin use, those receiving a statin and carrying the SREBF1 T allele exhibited higher total cholesterol levels (p = 0.01), triglyceride levels (p = 0.04) and low-density lipoprotein levels (p = 0.03). A regression analysis controlling for gender differences in lipids showed that the SREBF1 T allele and statin interaction remained only for total cholesterol levels (F[4,149] = 5.8; p < 0.0001). CONCLUSION:For schizophrenia individuals with the SREBF1 rs11868035 T allele, incomplete response to statin medications may be seen. Future investigations may allow for personalizing dyslipidemia treatment based on pharmacogenetics within schizophrenia.

SUBMITTER: Vassas TJ 

PROVIDER: S-EPMC4000704 | biostudies-literature | 2014 Jan

REPOSITORIES: biostudies-literature

altmetric image

Publications

Pharmacogenomics of sterol synthesis and statin use in schizophrenia subjects treated with antipsychotics.

Vassas Thomas J TJ   Burghardt Kyle J KJ   Ellingrod Vicki L VL  

Pharmacogenomics 20140101 1


<h4>Objective</h4>Patients with schizophrenia treated with antipsychotics often develop metabolic side effects including dyslipidemia. Antipsychotics potentially upregulate gene expression of a lipid metabolism pathway protein called SREBP via SREB transcription factors (SREBFs). Genetic variation within SREBF may contribute to dyslipidemias and lipid medication efficacy within schizophrenia.<h4>Results</h4>A cross-sectional study of 157 patients were genotyped for SREBF1 (rs11868035) and SREBF2  ...[more]

Similar Datasets

| S-EPMC5106233 | biostudies-literature
| S-EPMC3622480 | biostudies-literature
| S-EPMC3593824 | biostudies-literature
| S-EPMC3722141 | biostudies-literature
| S-EPMC6009243 | biostudies-literature
| S-EPMC7230415 | biostudies-literature
| S-EPMC5704497 | biostudies-other
| S-EPMC4641753 | biostudies-literature
| S-EPMC6681158 | biostudies-literature
| S-EPMC5702875 | biostudies-other